TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak reported a sale of 543 shares of common stock at $2.67 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting of previously granted restricted stock units and do not represent a discretionary sale. After this transaction, Marshak directly holds 125,101 shares of common stock.
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak reported a sale of 543 shares of common stock at $2.67 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting of previously granted restricted stock units and do not represent a discretionary sale. After this transaction, Marshak directly holds 125,101 shares of common stock.
TriSalus Life Sciences director Mats Wahlstrom bought additional common stock in the open market. He acquired 60,000 shares at a weighted average price of $2.53 per share, with individual trades priced between $2.52 and $2.56. Following this purchase, he holds 147,555 shares directly.
Wahlstrom is also associated with significant indirect holdings. HW Investment Partners, LLC holds 1,370,028 shares, where he is a managing member and he disclaims beneficial ownership beyond his economic interest. Leonard Capital LLC holds 1,444,447 shares, over which he and his spouse share voting and investment discretion.
TriSalus Life Sciences director Mats Wahlstrom bought additional common stock in the open market. He acquired 60,000 shares at a weighted average price of $2.53 per share, with individual trades priced between $2.52 and $2.56. Following this purchase, he holds 147,555 shares directly.
Wahlstrom is also associated with significant indirect holdings. HW Investment Partners, LLC holds 1,370,028 shares, where he is a managing member and he disclaims beneficial ownership beyond his economic interest. Leonard Capital LLC holds 1,444,447 shares, over which he and his spouse share voting and investment discretion.
TriSalus Life Sciences director Michael P. Stansky reported significant open-market buying of the company’s common stock. On May 15, 2026, an entity he manages, Skyview Investments LLC, purchased 200,000 shares at a weighted average price of $2.50 per share, bringing its holdings to 399,698 shares held indirectly. On the same date, he also purchased 410,000 shares directly at a weighted average price of $2.50 per share, increasing his direct ownership to 1,240,722 shares. The filing notes that each block was acquired through multiple trades within stated price ranges.
TriSalus Life Sciences director Michael P. Stansky reported significant open-market buying of the company’s common stock. On May 15, 2026, an entity he manages, Skyview Investments LLC, purchased 200,000 shares at a weighted average price of $2.50 per share, bringing its holdings to 399,698 shares held indirectly. On the same date, he also purchased 410,000 shares directly at a weighted average price of $2.50 per share, increasing his direct ownership to 1,240,722 shares. The filing notes that each block was acquired through multiple trades within stated price ranges.
TriSalus Life Sciences CEO Mary T. Szela bought 39,682 shares of common stock in an open-market purchase at a weighted average price of $2.59 per share. After this transaction, she directly holds 1,065,215 common shares.
A footnote explains these purchases are matchable under Section 16(b) against earlier sales that were made solely to cover tax withholding on vesting restricted stock units. The filing states she paid $27,573.70 to the company, equal to the profit from this short-swing transaction.
TriSalus Life Sciences CEO Mary T. Szela bought 39,682 shares of common stock in an open-market purchase at a weighted average price of $2.59 per share. After this transaction, she directly holds 1,065,215 common shares.
A footnote explains these purchases are matchable under Section 16(b) against earlier sales that were made solely to cover tax withholding on vesting restricted stock units. The filing states she paid $27,573.70 to the company, equal to the profit from this short-swing transaction.
TriSalus Life Sciences Chief Financial Officer Patience David bought 7,100 shares of the company’s Common Stock in an open-market transaction at $2.43 per share on May 15, 2026. Following this purchase, she directly owns 275,757 Common Stock shares.
TriSalus Life Sciences Chief Financial Officer Patience David bought 7,100 shares of the company’s Common Stock in an open-market transaction at $2.43 per share on May 15, 2026. Following this purchase, she directly owns 275,757 Common Stock shares.
TriSalus Life Sciences, Inc. director Gary B. Gordon reported an open-market purchase of company stock. On May 15, 2026, he bought 10,000 shares of Common Stock at $2.46 per share, increasing his direct ownership to 72,510 shares after the transaction.
TriSalus Life Sciences, Inc. director Gary B. Gordon reported an open-market purchase of company stock. On May 15, 2026, he bought 10,000 shares of Common Stock at $2.46 per share, increasing his direct ownership to 72,510 shares after the transaction.
TriSalus Life Sciences reports a beneficial ownership filing showing 5,374,117 shares held by First Light Asset Management, LLC and Mathew P. Arens, representing 8.75% of the company’s common stock as stated in Item 4.
The filing is a joint Schedule 13G disclosing shared voting and dispositive power of 5,374,117 shares by both the Manager and Mr. Arens; the filing identifies the Manager as investment adviser to accounts and private funds and notes Mr. Arens’ control of the Manager.
TriSalus Life Sciences reports a beneficial ownership filing showing 5,374,117 shares held by First Light Asset Management, LLC and Mathew P. Arens, representing 8.75% of the company’s common stock as stated in Item 4.
The filing is a joint Schedule 13G disclosing shared voting and dispositive power of 5,374,117 shares by both the Manager and Mr. Arens; the filing identifies the Manager as investment adviser to accounts and private funds and notes Mr. Arens’ control of the Manager.
TriSalus Life Sciences director Kerry R. Hicks reported new equity awards and updated holdings. Hicks received 28,201 restricted stock units payable in common stock, which fully vest on May 14, 2026, subject to continued service. He was also granted 56,403 director stock options with a $2.52 exercise price, expiring on May 13, 2036, that vest on the same date. Following these grants, Hicks directly holds 542,790 shares of common stock and 145,625 director stock options. Indirect holdings include 1,370,028 shares through HW Investment Partners, LLC, 322,737 shares via The Kerry Raymond Hicks Dynasty Trust, and 81,845 shares held by Millennium Trust Company, LLC, with beneficial ownership in certain entities disclaimed except for his pecuniary interest.
TriSalus Life Sciences director Kerry R. Hicks reported new equity awards and updated holdings. Hicks received 28,201 restricted stock units payable in common stock, which fully vest on May 14, 2026, subject to continued service. He was also granted 56,403 director stock options with a $2.52 exercise price, expiring on May 13, 2036, that vest on the same date. Following these grants, Hicks directly holds 542,790 shares of common stock and 145,625 director stock options. Indirect holdings include 1,370,028 shares through HW Investment Partners, LLC, 322,737 shares via The Kerry Raymond Hicks Dynasty Trust, and 81,845 shares held by Millennium Trust Company, LLC, with beneficial ownership in certain entities disclaimed except for his pecuniary interest.
TriSalus Life Sciences director Mats Wahlstrom reported new equity compensation grants. He received 34,226 restricted stock units that vest fully on May 14, 2026, payable in common stock, subject to his continued board service.
He also received a Retainer RSU Award of 37,602 units, taken in lieu of 2026 cash board retainer fees. These RSUs vest in three equal quarterly installments through the remainder of 2026, conditioned on continued service. In addition, he was granted a director stock option for 75,204 shares of common stock at an exercise price of $2.5200 per share, vesting in full on May 14, 2026 and expiring on May 13, 2036.
The filing also shows substantial indirect common stock holdings through Leonard Capital LLC and HW Investment Partners, LLC, where Wahlstrom shares voting and investment discretion, and he disclaims beneficial ownership of HW Investment securities beyond his pecuniary interest.
TriSalus Life Sciences director Mats Wahlstrom reported new equity compensation grants. He received 34,226 restricted stock units that vest fully on May 14, 2026, payable in common stock, subject to his continued board service.
He also received a Retainer RSU Award of 37,602 units, taken in lieu of 2026 cash board retainer fees. These RSUs vest in three equal quarterly installments through the remainder of 2026, conditioned on continued service. In addition, he was granted a director stock option for 75,204 shares of common stock at an exercise price of $2.5200 per share, vesting in full on May 14, 2026 and expiring on May 13, 2036.
The filing also shows substantial indirect common stock holdings through Leonard Capital LLC and HW Investment Partners, LLC, where Wahlstrom shares voting and investment discretion, and he disclaims beneficial ownership of HW Investment securities beyond his pecuniary interest.
TriSalus Life Sciences director Gary B. Gordon received equity awards in the form of common stock and stock options. The filing reports grants of 24,553 and 28,201 shares of common stock at a price of $0.00 per share, reflecting restricted stock unit awards.
One RSU award fully vests on the one-year anniversary of the grant date of May 14, 2026, while a separate retainer RSU award vests in three equal quarterly installments through the remainder of 2026, in lieu of cash board fees. In addition, Gordon received a director stock option covering 56,403 shares of common stock at an exercise price of $2.52 per share, expiring in 2036, which also fully vests on the one-year anniversary of the grant date.
TriSalus Life Sciences director Gary B. Gordon received equity awards in the form of common stock and stock options. The filing reports grants of 24,553 and 28,201 shares of common stock at a price of $0.00 per share, reflecting restricted stock unit awards.
One RSU award fully vests on the one-year anniversary of the grant date of May 14, 2026, while a separate retainer RSU award vests in three equal quarterly installments through the remainder of 2026, in lieu of cash board fees. In addition, Gordon received a director stock option covering 56,403 shares of common stock at an exercise price of $2.52 per share, expiring in 2036, which also fully vests on the one-year anniversary of the grant date.